Table 1.
The baseline characteristics of the chronic graft vs. host disease digital twin cohort at first-line treatment (flGvHD DT cohort).
| Characteristic | Digital twin baseline patient characteristics—parameter values | Data from real-world sources used for constructing the DT | ||
|---|---|---|---|---|
| No. of cohorts | No. of patients | |||
| Demographic characteristic | Age (yrs), median (min-max) | 52.2 (18–84) | 21 | 1238 |
| Female | 41% | 17 | 1521 | |
| Male | 59% | 28 | 2017 | |
| Duration (months, min-max) | allo-HCT - cGvHD | 7.58 (1–88) | 13 | 1152 |
| cGvHD - enrollment | 1.33 (0–62) | 9 | 467 | |
| cGvHD NIH severity score | Mild | 16% | 14 | 1443 |
| Moderate | 55% | 21 | 1734 | |
| Severe | 30% | 21 | 1734 | |
| cGvHD type | Classic | 27% | 9 | 1249 |
| Overlap | 72% | 9 | 1249 | |
| Onset type | De novo | 38% | 11 | 430 |
| Quiescent | 39% | 10 | 409 | |
| Progressive | 24% | 11 | 737 | |
| Underlying disease | AML | 36% | 12 | 334 |
| MDS | 15% | 10 | 284 | |
| ALL | 14% | 12 | 334 | |
| CML | 13% | 7 | 236 | |
| NHL | 10% | 9 | 203 | |
| MM | 8% | 10 | 286 | |
| CLL | 5% | 5 | 191 | |
| Organ involvement | Mouth | 71% | 11 | 876 |
| Skin | 68% | 13 | 929 | |
| Eye | 52% | 12 | 897 | |
| Liver | 48% | 14 | 957 | |
| GI | 36% | 11 | 743 | |
| Lung | 35% | 10 | 746 | |
| Joint/fascia | 25% | 10 | 541 | |
| Conditioning | Myeloablative | 49% | 9 | 1135 |
| Nonmyeloablative | 46% | 7 | 779 | |
| Graft sex match (host to recipient) | M to M | 33% | 4 | 195 |
| F to M | 25% | 11 | 826 | |
| M to F | 21% | 4 | 195 | |
| F to F | 19% | 4 | 195 | |
| Graft cell source | PBSC | 87% | 24 | 1816 |
| BM | 7% | 22 | 1888 | |
| UCB | 6% | 15 | 1700 | |
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, BM bone marrow, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, DT digital twin, F female, GI gastrointestinal tract, MDS myelodysplastic syndrome, MM multiple myeloma, M male, NHL non-Hodgkin lymphoma, PBSC peripheral blood stem cells, UCB umbilical cord blood.